FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

[ad_1]

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.

[ad_2]

Source link